About Lytica Therapeutics
Lytica Therapeutics is a company based in Cambridge (United States) founded in 2019. Lytica Therapeutics has raised $5.82 million across 4 funding rounds from investors including CARB-X. Lytica Therapeutics offers products and services including SPACE Platform and SIP Antibody Co-conjugates. Lytica Therapeutics operates in a competitive market with competitors including Orakl Oncology, Oncodesign, LumaBridge, Orange Grove Bio LLC and Axios Biosciences, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lytica Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.82 M (USD)
in 4 rounds
-
Latest Funding Round
$6 M (USD), Debt – Conventional
Feb 28, 2025
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lytica Therapeutics
Lytica Therapeutics offers a comprehensive portfolio of products and services, including SPACE Platform and SIP Antibody Co-conjugates.
Enables modular antibody functionalization for enhanced oncology treatments
Increases ADC internalization and efficacy for cancer applications
People of Lytica Therapeutics
Unlock access to complete
Unlock access to complete
Scientific Team
6 people
Operations Team
3 people
Leadership Team
2 people
Senior Team
1 people
Unlock access to complete
Funding Insights of Lytica Therapeutics
Lytica Therapeutics has successfully raised a total of $5.82M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $6 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lytica Therapeutics
Lytica Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Locked | Locked | Locked |
Investor details for Lytica Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lytica Therapeutics
Investment portfolio details for Lytica Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lytica Therapeutics
Detailed financials for Lytica Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lytica Therapeutics Comparisons
Peer comparison for Lytica Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lytica Therapeutics
Lytica Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, LumaBridge, Orange Grove Bio LLC and Axios Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
|
|
| Locked | Locked | Locked |
Preclinical assessment services for anti-cancer therapies are provided.
|
|
| Locked | Locked | Locked |
Provider of oncology clinical research, regulatory affairs, and data management services
|
|
| Locked | Locked | Locked |
Provider of preclinical development services
|
|
| Locked | Locked | Locked |
Creates innovative platforms for anti-cancer drug development.
|
Detailed competitors of Lytica Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lytica Therapeutics
Complete news archive for Lytica Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lytica Therapeutics
Lytica Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Lytica Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jim LaTorre is the current CEO of Lytica Therapeutics.
Lytica Therapeutics is a funded company, having raised a total of $5.82M across 4 funding rounds to date.
Lytica Therapeutics was founded in 2019 and is headquartered in Cambridge, United States. Operations are centered on the development of therapeutic drugs within the biotechnology sector. Research and innovation efforts are directed toward creating treatments for various health conditions. The company is led by CEO Jim LaTorre, with activities focused on advancing pharmaceutical solutions in a competitive industry landscape.
Lytica Therapeutics's top competitors include Oncodesign, Orakl Oncology and Orange Grove Bio LLC.
Lytica Therapeutics offers SPACE Platform and SIP Antibody Co-conjugates.
Lytica Therapeutics has 1 investor. Key investors include CARB-X.